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The advent of recombinant peptide technology offers the
potential to use one or several peptides to treat a variety of
gastrointestinal conditions. However, although cell culture
and animal models have shown proof of concept, we are
still at a relatively early stage in translating their use to
standard clinical practice. Similarly, peptide and non-
peptide antagonists of growth factor receptors show great
potential as novel antichemotherapy agents. However,
their actual place in clinical practice has yet to be
established.
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O
ver the past few years, the combination of
rapid advances in recombinant peptide
technology and a much greater under-
standing of the pathophysiological role of growth
factors has resulted in several clinical trials
utilising growth factors or their antagonists for
the treatment of a variety of gut conditions. In
general, peptide agonists are being tested and
used for stimulation of gut growth and repair
whereas the peptide antagonists are beginning to
find value for their chemotherapeutic (anti-
cancer) activity. This review summarises the
current state of play.
There are at least 30 different peptides
produced within the gut that are involved in
mucosal integrity and repair. Although there
have been many papers examining the effect of
individual peptides on gastrointestinal function,
there are few data regarding their function as
part of an integrated defence mechanism in vivo.
This is important as modulation of tissue mass is
not simply dependant on the rate of proliferation
but on the equilibrium established in vivo
between cell production, migration, and loss
(including apoptosis), with several peptides
influencing all of these activities.
COMPLEXITY AND MULTIPLE ACTIONS OF
RECEPTOR SIGNALLING
One of the major issues relating to the use of
growth factor agonists and antagonists is that
because of the complexity of receptor activation
and signalling and the multiple pathophysio-
logical functions that operate through these
systems, there may be a higher than usual risk
of unexpected adverse events. As an example,
the signalling pathways and actions of epidermal
growth factor receptor (EGFR) activation are
briefly described.
EGFR is a typical transmembrane tyrosine
kinase signalling receptor. It consists of an
extracellular ligand binding region, a membrane
spanning segment that anchors the receptor to
the cell membrane, and an intracellular segment
that possesses tyrosine kinase activity.1 Ligand
binding results in receptor dimerisation and
activation of the tyrosine kinase enzyme within
the intracellular domain of the receptor.2 This
tyrosine kinase activation initiates signalling
cascades via PI3-K, Akt, and STAT, or via the
Ras/Raf MAPK pathways which, acting via
several mechanisms including altered gene
expression, ultimately results in increased pro-
liferation, resistance to radio- or chemotherapy,
increased cell survival via an antiapoptotic
mechanism, as well as influencing crypt fission
and angiogenesis.3 In addition, EGFR activation
can also affect acid and bicarbonate secretion,
sodium and glucose uptake, mucus production,
smooth muscle contractility, and increased cyto-
protection by poorly identified mechanisms.
Furthermore, the realisation that heterodimer-
isation of the EGFR with other members of the
erb receptor family can occur adds to the
complexity of the situation and is an area which
is relatively poorly understood.
GROWTH FACTOR AGONISTS
What diseases may peptide agonists (or non-
peptide analogues) be useful for? The high
efficacy of acid suppressants and Helicobacter
pylori eradication regimens probably limit the
value of such approaches for oesophagitis and
peptic ulceration, except in the most intractable
of cases. There are however a number of serious
gastrointestinal pathologies where novel thera-
pies might prove useful, including their use for
multiorgan failure,4 necrotising enterocolitis,5
and liver protection and regeneration.6 Three
conditions worthy of particular focus are short
bowel syndrome, chemotherapy induced muco-
sitis, and inflammatory bowel disease. These are
discussed further below.
‘‘Systemic administration of individual
growth factors, such as EGF and glucagon-
like peptide 2 (GLP-2), may provide an
important alternative acting via stimulation
of bowel growth’’
Peptide therapy for short bowel syndrome
is already in common usage as octreotide
Abbreviations: EGF, epidermal growth factor; EGFR,
epidermal growth factor receptor; GLP-2, glucagon-like
peptide 2; TGF-b, transforming growth factor b; GnRH,
gonadotrophin releasing hormone; TKI, tyrosine kinase
inhibitor
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(somatostatin analogue without significant growth factor
effects) already has a place in reducing ileostomy output.
However, when metabolic balance cannot be maintained,
present therapeutic options consist of long term parenteral
(intravenous) feeding or, in a few selected cases, small bowel
transplantation. Unfortunately, both of these options are
associated with high cost and morbidity. Systemic adminis-
tration of individual growth factors, such as EGF and
glucagon-like peptide 2 (GLP-2), may provide an important
alternative acting via stimulation of bowel growth. Evidence
in favour of this approach includes the findings that systemic
administration of EGF stimulated bowel growth in rats
receiving total parenteral nutrition7 and oral EGF helped
restore glucose transport and phlorizin binding in rabbit
intestines following jejunal resection.8 Similarly, GLP-2 has
been shown to improve intestinal adaptation and nutrient
absorption after major small bowel resection in rats.9 A recent
study has demonstrated that GLP-2 also acts as a tropic factor
in humans with short bowel syndrome, causing a significant
trophic effect on the intestine by stimulating enterocyte
proliferation while at the same time reducing rates of
enterocyte apoptosis. Significantly greater intestinal absorp-
tion of energy, water, and nitrogen was also seen.10 Further
larger trials are ongoing.
In recent years, high dose chemotherapy protocols are
being increasingly used in an attempt to improve cancer cure
rates. As a result of this escalation in dosing, toxic side effects
on the bone marrow or gastrointestinal tract can be the factor
limiting the dose or duration of treatment. The breakdown in
mucosal integrity may range from oral stomatitis to massive
intestinal ulceration. Strategies to protect these tissues and
encourage their recovery may therefore facilitate the use of
higher dosage with greater potential for cure. Several peptide
growth factors, such as EGF and transforming growth factor
b (TGF-b), are currently under examination. Examples
include the findings that EGF enhances repair of rat
intestinal mucosa damaged by methotrexate,11 TGF-b amel-
iorates chemotherapy induced mucositis,12 and administra-
tion of a cheese whey derived preparation reduced
methotrexate induced gut injury in mice.13 Although these
preliminary studies have often shown great initial promise, it
is important to realise that equivalent benefit has yet to be
confirmed in clinical trials. For example, in a phase I clinical
study of patients undergoing chemotherapy, EGF had only a
minor beneficial effect in reducing mouth ulceration.14
‘‘If peptides with growth stimulatory or inhibitory effects
are to be used, timing of administration is likely to be
critical’’
If peptides with growth stimulatory or inhibitory effects
are to be used, timing of administration is likely to be critical;
growth arresting factors might protect bone marrow or gut
from the damaging effects of chemotherapy (which tends to
affect areas with the highest cell turnover) if given prior to
chemotherapy. In contrast, growth stimulating factors might
‘‘rescue’’ recovery of injured areas if they are administered
following chemotherapy. This latter approach is already being
used clinically as colony stimulating growth factor is used to
stimulate bone marrow recovery following chemotherapy.
The aetiology of ulcerative colitis and Crohn’s disease is
unknown, and current treatment of these severe incapacitat-
ing conditions therefore has to be on an empiric basis. Several
peptide growth factors are at various stages of investigation.
These include EGF, platelet derived growth factor, TGF-b,
insulin-like growth factor I, keratinocyte growth factor,
trefoil peptides, and combination therapy of multiple pep-
tides in the form of bovine colostrum.15 Recently, both
colostrum and EGF topical therapy has been shown to be
beneficial in small pilot studies16 17 whereas a more dis-
appointing result was seen with systemic keratinocyte
growth factor.18
GROWTH FACTOR ANTAGONISTS
There are two sides to every equation, and peptide growth
factors are no exception. At the same time as peptide agonists
are gaining clinical prominence, peptide and non-peptide
growth factor antagonists are showing promise as chemo-
therapeutic agents for many different forms of malignancy,
including gynaecological, respiratory, and gastroenterological
tumours.
‘‘Peptide and non-peptide growth factor antagonists are
showing promise as chemotherapeutic agents for many
different forms of malignancy’’
A phase II clinical trial with the gonadotrophin releasing
hormone (GnRH) antagonist cetrorelix in patients with
ovarian or mullerian carcinoma who were refractory to
platinum chemotherapy showed highly promising results
when tested in a limited number of patients.19 In addition,
cytotoxic GnRH analogues have been developed where, for
example, doxorubicin has been covalently coupled to these
GnRH analogues.20
Based on extensive biological studies, it has become
evident that growth factors, their receptors, and/or their
related signal transduction pathways, are aberrant in many,
if not most, gastrointestinal cancers. The form by which
cellular activation takes place varies between tumours and
can result from mutation of the receptor itself causing
constitutive activation of the receptor, overexpression of the
number of normal receptors by the tumour, or by decreased
inactivation of the phosphorylated receptor.
The initial rationale for targeting the EGFR in the clinical
cancer setting stems from expression studies that showed
that EGFR was highly expressed (and frequently coexpressed
with TGF-a) in a large proportion of common cancers and
was associated with invasion, metastasis, late stage disease,
and poor outcome.21 22 Gastrointestinal tract cancers, includ-
ing colorectal, pancreatic, oesophageal, and head and neck
cancers, have been reported to show some of the highest
levels of EGFR overexpression when analysed using standard
immunohistochemistry (although there is always the concern
of methodological problems when just using this approach).
Current EGFR targeted therapies fall into several groups.
One group of compounds of EGFR inhibitors that have been
developed are known as small molecule tyrosine kinase
inhibitors (TKIs). TKIs inhibit the internal catalytic domain
TK activity of the EGFR, thus effectively preventing receptor
autophosphorylation and subsequent signalling cascades.
Clinically, there are at least seven EGFR TKI in phase II
and III trials, one of which (Iressa, ZD1839) is licensed for
monotherapy in refractory lung cancer.23 Some of these drugs
also inhibit the erB-2 (HER2) pathway, and one of these, a
quinazoline compound (CI-1033), is an irreversible oral pan-
EGFR inhibitor (that is, blocks activity downstream of four of
the closely related EGFR/HER family). Although some of
these compounds are showing promise for breast cancer
therapy, no small molecule EGFR TKI has yet fulfilled its
clinical promise with regard to gastrointestinal cancers
(although several trial results are awaited).
‘‘A further group of compounds that are under active
investigation are the EGFR (HER1) monoclonal blocking
antibodies’’
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A further group of compounds that are under active
investigation are the EGFR (HER1) monoclonal blocking
antibodies. At least four anti-EGFR1 monoclonal antibodies
are in late stage clinical development, culminating in
Cetuximab recently being awarded its therapeutic licence in
the treatment of chemotherapy refractory (specifically
Irinotecan refractory) metastatic colorectal cancer.
Cetuximab (Erbitux) is a chimeric IgG1 high affinity
monoclonal antibody directed against the extracellular
domain of the human EGFR (HER1). This product has been
shown in preclinical studies to enhance antitumour activity
when used in combination with chemotherapy and radiation
therapy. Cetuximab is known to stimulate receptor inter-
nalisation and also prevent binding of TGF-a to the EGFR.
Two phase II studies,24 one of which was randomised (BOND
study), have demonstrated significant efficacy with improve-
ments in progression free survival in metastatic colorectal
cancer when used in combination with Irinotecan
chemotherapy. More impressively, in patients refractory to
Irinotecan, 20% could be converted to significant responses
with resensitisation to Irinotecan with the sequential addi-
tion of Cetuximab. Monotherapy with Cetuximab also had
efficacy in this study. However, somewhat surprisingly, there
was no correlation of response rates with levels of EGFR
overexpression in the tumours in either study. In contrast,
but somewhat ironically, there does appear to be a strong
positive correlation of efficacy with skin toxicity and this
general pattern of skin toxicity is emerging as a trend for the
use of the general class of EGFR inhibitors.
‘‘Monoclonal antibody therapy may provide an important
novel approach for patients with inoperable or metastatic
colorectal cancer’’
Monoclonal antibody therapy may therefore provide an
important novel approach for patients with inoperable or
metastatic colorectal cancer. EGFR blockade may not how-
ever be the only receptor to target as Avastin (Genentech,
Roche), an antivascular endothelial growth factor mono-
clonal antibody, has also recently been shown to have a
significant overall survival benefit (when used in combina-
tion with Irinotecan) in a phase III randomised trial in chemo
naı¨ve patients with metastatic colorectal cancer.25 Other
approaches to manipulate growth factor ligands and their
receptors that are under active investigation include bispe-
cific and single chain antigrowth factor receptor antibodies,
immunotoxin conjugates, and antisense oligonucleotides.26
Numerous clinical studies on the use of growth factor
inhibitors in the treatment of gastrointestinal cancers are
underway. Of equal interest, but at a much earlier stage, is
the idea that growth factor receptor blockers may also be
useful in preventing or reducing the risk of progression of
premalignant conditions, such as in Barrett’s oesophagus and
the adenoma-carcinoma sequence in colonic lesions.
WHAT ARE THE RISKS OF GROWTH FACTOR
AGONISTS?
Advances in recombinant peptide technology now allow us to
produce virtually pure peptide at moderate cost. This removes
the concern of contamination with infectious agents (as seen
in patients treated with growth hormone developing
Creutzfeldt-Jakob disease) and the problems of development
of antibodies to purified peptides obtained from other species
(as seen with porcine insulin). There are however a number
of areas of potential concerns, including the major worry that
systemic use of potent growth factors may induce tumour
progression in the gut area that is being treated (as for
example when used for the treatment of colitis) or in distant
organs (for example, lung tumours). As stated earlier, it is
certainly true that several of these tumours appear to express
functional growth factor receptors. A clinical correlate of
this concern is that patients with acromegaly (increased
systemic levels of the peptide ‘‘growth factor’’ growth
hormone) have an increased risk of development of colonic
carcinoma.27
In this issue of Gut, Thulsen and colleagues28 report that
one month’s daily systemic treatment with GLP-2 (or its
analogue Gly2-GLP-2) increased the size of colonic polyps in
mice that had been pretreated with the carcinogen dimethyl-
hydrazine [see page 1145]. A similar finding has been
reported when systemic EGF was administered long term to
‘‘Min mice’’.29 Min mice are used as a model of the human
defect seen in APC where the mouse homologue of the
human APC gene has been deleted. In this model, for reasons
that are poorly understood, the mouse phenotype tends to
give predominantly small intestinal polyps, rather than
colonic polyps. In both of these reports, size of tumour
burden, rather than the number of tumours, was increased.
The use of animal models to determine the potential risk of
peptide growth factor therapy in inducing cancer develop-
ment in humans will always have its limitations and, to date,
has provided somewhat contradictory results. In mice given
the carcinogen dimethyhydrazine, an increased number of
anal squamous cell carcinomas were seen if EGF was
coadministered on alternate days for two weeks but no
change in the number or size of colonic tumours was
observed.30 In contrast, an antagonistic relationship between
EGF and azoxymethane on proliferation and tumour growth
was reported following intracolonic administration of EGF.
This suggests that while luminal EGF can increase normal
colonic epithelial growth, it does not potentiate carcinogen-
esis.31
‘‘The use of animal models to determine the potential risk
of peptide growth factor therapy in inducing cancer
development in humans will always have its limitations’’
In contrast with the results seen administering EGF and
carcinogens to normal mice, a different series of conclusions
have been reached when using genetically modified Min
mice. These studies have suggested that normal EGFR
activity is required for establishment of intestinal tumours
as impaired EGFR signalling or pharmacological inhibition of
EGFR resulted in a large reduction in polyp number, but not
apparently of polyp progression.32 In addition, administration
of the combination of a chemopreventative drug (sulindac)
and an irreversible inhibitor of the EGFR dramatically
reduced the tumour number in Min mice.33 Taken in the
context of a need for caution, these results raise sufficient
concerns that the risk/benefit for their use has to be carefully
weighed and that any patient given such therapies will need
regular subsequent supervision.
How can we reduce the risk? As for the use of non-steroidal
anti-inflammatory drugs, administering the lowest possible
dosage for the shortest time needed to achieve the required
goal seems logical. In addition, the use of oral, as opposed to
systemic, administration of growth factors provides one
possible approach to limit regions exposed to these pharma-
cological levels of growth factors. However, for EGF and the
trefoil peptides, the oral doses required to treat gastrointest-
inal damage may be up to a thousand times greater
than when the peptide is given systemically, making oral
therapy much more expensive. Stabilising growth factor
peptide molecules against digestion in the small intestine is
likely to be difficult due to the many different proteolytic
enzymes produced by the pancreas. Possible strategies
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include administering the peptide in a site specific release
formulation to overcome these problems.
WHAT ARE THE RISKS OF GROWTH FACTOR
ANTAGONISTS?
As stated earlier, peptide growth factors have numerous
effects. It is therefore possible that administration of these
antagonists can have adverse effects on many different sites.
Disruption or ‘‘knockout’’ models of various growth factors
using transgenic models well demonstrate these concerns.
Knockout of individual ligands, such as EGF or TGF-a, causes
minimal problems on phenotype although they may be
associated with an increased susceptibility to injurious
agents.34 35 Patients taking non-steroidal anti-inflammatory
drugs or similar drugs may therefore be at risk of increased
side effects such as gastric ulceration. Based on animal
models, the risks associated with complete receptor blockade
are even higher. For example, knockout mice that have had
the EGFR receptor completely inactivated have a lethal
phenotype with problems in multiple organs, including gut
and respiratory abnormalities.36
SUMMARY
The advent of recombinant peptide technology offers the
potential to use one or several (to elicit synergistic responses)
peptides to treat a variety of gastrointestinal conditions. It is
important to note however that although cell culture and
animal models have shown proof of concept, we are still at a
relatively early stage in translating their use to standard
clinical practice. Similarly, peptide and non-peptide antago-
nists of growth factor receptors show great potential as novel
antichemotherapy agents.. However, their actual place in
clinical practice is still at an early stage (fig 1) and vigilance is
required to check for unexpected side effects at remote sites.
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Robin Spiller, Editor
A calcified caecal mass
Clinical presentation
A 64 year old woman with a history of Bentall operation and maintenance haemodialysis
due to multiple myeloma presented with a positive faecal occult blood test. She denied
abdominal symptoms. Physical examination was unremarkable. Leucocytosis was absent.
Colonoscopy showed a globular submucosal tumour with the appendiceal orifice (arrow) on
its top (fig 1). Computed tomography demonstrated a cystic lesion with ‘‘eggshell’’-like
mural calcification (arrow) in the expected region of the appendix (fig 2).
Question
What is the diagnosis?
See page 1081 for answer
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Figure 1 Colonoscopy showing a globular submucosal tumour with the
appendiceal orifice (arrow) on its top.
Figure 2 Computed tomography demonstrating a cystic lesion with
‘‘eggshell’’-like mural calcification (arrow) in the expected region of the
appendix.
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